

1 **Supplemental Table S2.** Characteristics of patients with gliptin-associated autoimmune bullous diseases (AIBDs).

Characteristic	Case reports (1-14) n = 40	Béné et al. (15) n = 42	Benzaquen et al. (16) n = 28	This study n = 17
Gliptin-associated, n	42 BPs	42 (28%) BPs among 150 ADRs ^a	28 (46%) BPs among 61 diabetics ^b	24 (38%) MMPs among 64 diabetics
Age, mean (range), years	75 (59–93)	74 (45–91)	79.1 +/- 7	69 (48–81)
Female/male, n, sex ratio	19/21 (0.9)	18/24 (0.75)	11/17 (0.65)	9/8 (1.1)
Time to AIBD onset, median (range)	32 (4–192) wk	40 wk (8 d–148 wk)	33 wk (10 d–156 wk)	136 (4–588) wk
Vildagliptin, n (%)	19 (45%)	31 (74%)	14 (50%)	11 (65%)
Sitagliptin, n (%)	10 (24%) ^c	10 (24%)	10 (36%)	5 (29%)
Saxagliptin, n (%)	8 (19%)	1 (2%)	4 (14%)	1 (6%)
Other gliptin(s), n (%)	5 (12%) ^c	No	No	No
Dechallenge (suggestive), n	33 (26)	37 (34)	19 (18)	11 (7)
Time to AIBD clinical control, median (range)	NR	10 (5–15) d	Usual	8 (2–16) wk
Rechallenge , n	0	1 (positive)	1 (positive)	1 (positive)
No dechallenge (suggestive), n	8 (3)	5 (nd)	9 (4)	6 (2)

2 BP, bullous pemphigoid; ADRs, adverse drug reactions; MMP, mucous membrane pemphigoid; wk, week(s); d, day(s); NR, not reported.

3 ^a Compared vs. 0.6% of non-cases (odds ratio 67.5; 95% CI 47.1–96.9).4 ^b Compared vs. 18% of non-cases (odds ratio 2.64; 95% CI 1.19–5.85).5 ^c Other gliptins: 3 mixed, 1 alogliptin, 1 anagliptin.